American healthcare costs are sky-high; as treatments get pricier and the number of patients swells owing to an ageing population, they are getting higher. Chinese biotechnology is increasingly sophisticated and, as its companies gain scale, getting cheaper.
A growing number of American drugmakers, from start-ups to big pharma, rely on firms like WuXi AppTec and WuXi Biologics, which conduct drug research on behalf of clients and manufacture compounds used in drugmaking.
Already a subscriber? Log in
Read the full story and more at $9.90/month
Get exclusive reports and insights with more than 500 subscriber-only articles every month
ST One Digital
$9.90/month
No contract
ST app access on 1 mobile device
Unlock these benefits
All subscriber-only content on ST app and straitstimes.com
Easy access any time via ST app on 1 mobile device
E-paper with 2-week archive so you won't miss out on content that matters to you